ESMO Colloquia - Past Meetings

Meeting resources from the ESMO Colloquia can be viewed by ESMO members and non-members on OncologyPRO: the home of ESMO’s educational and scientific resources.

Past Events

Resources from ESMO Colloquium (ESMO Members only)

Thursday, 4 July 2019

ESMO Colloquium: Metastatic gastrointestinal cancer: How to deal with the complexity of multiple available drugs across lines of treatment?

ESMO Colloquia World GI 2019 Thumbnail

Room 115-116, 13:15-14:45
This educational activity is provided by ESMO and supported by Lilly Oncology.
View the ESMO Colloquium details

Learning Objectives
  • Review the optimal treatment options in successive lines of available therapies
  • Discuss best sequencing based on level of evidence
  • Learn about the use of biomarker for decision making
  • Analyse the present guidelines, algorithms and ESMO-MCBS scores as tools for selection

Resources from ESMO Colloquium (ESMO Members only)

View the complete ESMO Asia Congress 2019 programme online

Friday, 22 November 2019

ESMO Colloquium: Biomarker-driven treatment decision in metastatic NSCLC

Hepatocellular carcinoma treatment thumb

Hall 407, 12:45 – 14:15
This educational activity is provided by ESMO and supported by Lilly Oncology.
View the ESMO Colloquium details

Learning Objectives
  • Review the optimal immunotherapy options for NSCLC in first-line
  • Updated knowledge on treatment of EGFR mutant NSCLC as single agent or in combination
  • Optimise the use of biomarkers for patient selection and management
  • Integrate new data within the most recent ESMO Guidelines

Sunday, 24 November 2019

ESMO Colloquium: Liquid biopsy in the management of solid tumours

Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) Thumbnail

Room 311, 11:00 - 12:30
This educational activity is provided by ESMO and supported by Guardant Health.
View the ESMO Colloquium details

Learning Objectives
  • Review the source material and the available technological aspects
  • Optimise the use of biomarkers from liquid biopsies at diagnosis for patient selection and management
  • Assess the role of repeated liquid biopsies at recurrence; understand potential experimental uses of liquid biopsy for assessment of treatment effect
  • Integrate new data within the most recent ESMO Guidelines and ESCAT
  • Provide an update on the use of liquid biopsies by medical oncologists in lung, breast, and colorectal cancers

Sunday, 24 November 2019

ESMO Colloquium: State of the art management of mCPRC

Immunotherapy of Lung Cancer: Alone or in Combination? Thumbnail

Summit 2, 11:00 - 12:30
This educational activity is provided by ESMO and supported by Astellas.
View the ESMO Colloquium details

Learning Objectives
  • How to best characterize metastatic castration resistant prostate cancer (mCRPC)
  • Understand the management of mCRPC with the new therapeutic options and related biomarkers
  • To elucidate the optimal treatment sequence in the management of mCRPC
  • To explore the role of immunotherapy in the management of mCRPC

Resources from ESMO Colloquium (ESMO Members only)

View the complete ESMO Congress 2019 programme online

Saturday, 28 September 2019

ESMO Colloquium: Emerging biotherapy strategies in the treatment of solid tumours: Hope, Hype and Hurdles

Emerging-Biotherapy-Strategies-in-the-Treatment-of-Solid-Tumours-Hope-Hype-and-Hurdles-EISAI-Thumb

Toledo Auditorium, 13:00-14:30
This educational activity is provided by ESMO and funded by Eisai Europe Ltd.
View the ESMO colloquium details

Learning Objectives
  • Understand how the development of TKI have changed practice and treatment prioritization
  • Review the overall outcome with the development of Immuno-Oncology and practice changes
  • Look forward to the development of Combined approaches with TKI and immuno-oncology

Sunday, 29 September 2019

ESMO Colloquium: Metastatic clear cell renal cell carcinoma: How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?

Metastatic-Clear-Cell-Renal-Cell-Carcinoma-What-Is-the-Best-Sequence-in-A-Multi-Line-Setting-IPSEN-Thumb

Cordoba Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Ipsen.
View the ESMO colloquium details

Learning Objectives
  • Review the 2019 algorithms from the ESMO Guidelines for the management of Renal Cell Carcinoma
  • Compare the outcome and clinical benefit (ESMO-MCBS) of the various therapeutic options according to risk factors upfront and in later lines.
  • Discuss the best sequencing of drug use considering the large choice of approved agents

Sunday, 29 September 2019

ESMO Colloquium: Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Relapsed-Refractory-FLT3-ITD-Mutated-Acute-Myeloid-Leukemias-AML-DAIICHI-SANKYO-Thumb

Toledo Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Daiichi Sankyo Europe GmbH.
View the ESMO colloquium details

Learning Objectives
  • Review the present characteristics and Guidelines for the management of Relapsed/Refractory AML
  • Understand the mechanism of action of FLT3 and its role in AML when mutated
  • Review the recent outcomes of FLT3-ITD as a target in Relapsed/Refractory AML

Sunday, 29 September 2019

ESMO Colloquium: Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal?

Metastatic-Gastro-Intestinal-Cancer-How-to-Best-Sequence-the-Treatment-Proposal-LILLY-Thumb

Alicante Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Lilly Oncology.
View the ESMO colloquium details

Learning Objectives
  • Based on case presentations
  • Discuss the best sequence and level of evidence
  • Learn how the use biomarkers in decision making
  • Review the guidelines algorithms and ESMO-MCBS scores as tools for selection

Monday, 30 September 2019

ESMO Colloquium: Pancreatic cancer: Can better understanding of biology improve resectability and survival?

Pancreatic-Cancer-Can-Better-Understanding-of-Biology-Improve-Resectability-and-Survival-CELGENE-Thumb

Alicante Auditorium, 13:00-14:30
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details

Learning Objectives
  • Learn on the biological peculiar aspects of pancreatic cancer and treatment resistance
  • Review the present state of art of medical treatment improving resectability and survival
  • Get the point of view of the specialized surgeon on resectabilitiy criteria and issues
  • Review the present development of new drugs including targeted and Immuno-oncology agents

Monday, 30 September 2019

ESMO Colloquium: Recurrent glioblastoma management: Challenges and opportunities

Recurrent-Glioblastoma-Management-Challenges-and-Opportunities-APOGENIX-Thumb

Salamanca Auditorium, 18:30-20:00
This educational activity is provided by ESMO and supported by Apogenix AG.
View the ESMO colloquium details

Learning Objectives
  • Review the present standard of care management of recurrent glioblastoma
  • Access the landscape of present new development for the treatment of recurrent glioblastoma
  • Understand the role and biological mechanisms of CD95/CD95 ligand (Fas/Fas ligand) signaling pathway
  • Deliver an update of the present clinical results of CD95/CD95 ligand (Fas/Fas ligand) blockade

Resources from ESMO Colloquium (ESMO Members only)

Wednesday, 10 April 2019

ESMO Colloquium - How to Best Use Immune Checkpoint Inhibitors in NSCLC: Single Agents or Combined With Chemotherapy?

How to Best Use Immune Checkpoint Inhibitors In NSCLC: Single Agents or Combined With Chemotherapy? Thumb

Room A, 11:45 – 13:15
This educational activity is provided by ESMO and supported by Lilly in collaboration with MSD.
View the ESMO Colloquium details

Learning Objectives

  • Review the optimal immunotherapy options for NSCLC in first line
  • Discuss the rationale for combining Immune Check Points (ICPs) among themselves or with cytotoxic drugs
  • Evaluate the role of anti-angiogenics in combination with Chemotherapy and ICPs treatment

Resources from ESMO Colloquium (ESMO Members Only)

Friday, 23 November 2018

ESMO Colloquium: Immunotherapy of lung cancer:  Alone or in combination?

Immunotherapy of Lung Cancer: Alone or in Combination? Thumbnail

Room 311, 12:45-14:15
This educational activity is provided by ESMO and supported by Lilly and Roche.
View the ESMO Colloquium details

Learning Objectives
  • Review the optimal immunotherapy options for NSCLC in 1st line
  • Discuss the rationale for combining immune checkpoints (ICPs) among themselves or with cytotoxic drugs
  • Evaluate the role of anti-angiogenics in combination with chemotherapy and ICPs
  • Acquire knowledge of recent Guidelines on 1st line NSCLC with ICP treatment

Friday, 23 November 2018

ESMO Colloquium: Oncology biosimilars in Asia

Oncology Biosimilars in Asia Thumbnail

Hall 404, 16:30-18:00
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO Colloquium details

Learning Objectives
  • Understand the state of play, in the Asia- Pacific community, concerning the development and uptake of oncology biosimilars (moAbs)
  • Inform the healthcare community about the existing challenges for the uptake of oncology biosimilars emerging from the recent survey conducted by ESMO
  • Discuss the example of India, a country producing biosimilars in the region
  • Assess the financial impact of oncology biosimilars on healthcare systems within the APAC region

Saturday, 24 November 2018

ESMO Colloquium: Updated therapeutic approach of castration-resistant prostate cancer (CRPC)

Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) Thumbnail

Room 324, 12:45-14:15
This educational activity is provided by ESMO and supported by Astellas.
View the ESMO Colloquium details

Learning Objectives
  • To review the peculiar aspects of CRPC
  • To evaluate the benefit of conventional chemotherapy in CRPC
  • To understand the impact of androgen receptor inhibition in CRPC
  • To get an update of potential development in immunotherapy of CRPC

Sunday, 25 November 2018

ESMO Colloquium: Metastatic gastric and oesophago-gastric cancers

Metastatic Gastric and Oesophagogastric Cancers Thumbnail

Room 324, 9:15-10:15
This educational activity is provided by ESMO and supported by Lilly.
View the ESMO Colloquium details

Learning Objectives

Review the optimal treatment options in 1st line according to the biomarker profile

  • Discuss treatment of patients fit for 2nd line, selection criteria, nutritional status impact
  • Learn about recent results of immunotherapy for metastatic gastric cancer
  • Acquire knowledge of recent Guidelines

Resources from ESMO Colloquium (ESMO Members only)

Saturday, 20 October 2018

ESMO Colloquium: Hepatocellular carcinoma (HCC) treatment: Now, next and beyond

Hepatocellular carcinoma treatment thumb

Room: ICM – Room 1, 13:00-14:30
This educational activity is provided by ESMO and supported by Eisai.
View the ESMO colloquium details

Learning Objectives
  • To enhance understanding of loco-regional therapy (LRT) options and the evidence base to support the optimal outcomes
  • To inspire debate regarding what the optimal transition is from LRT to first line systemic treatment for HCC
  • To present the first line systemic treatment options and the rationale to move beyond monotherapy in a first line setting

Saturday, 20 October 2018

ESMO Colloquium: Systemic therapies in unresectable hepatocellular carcinoma (HCC): 1st and later lines

Systemic therapies in unresectable hepatocellular carcinoma thumb

Room: ICM – Room 14B, 18:30-20:00
This educational activity is provided by ESMO and supported by IPSEN.
View the ESMO colloquium details

Learning Objectives
  • To better understand the biology of HCC and the potential targets to be used
  • To review the efficacy of targeted agents in unresectable HCC
  • To get an update on the present potential role of immune checkpoints inhibitors
  • To overview the possible future treatment strategies with new agents or combined modalities

Sunday, 21 October 2018

ESMO Colloquium: Immune checkpoint inhibitors: Are we ready for combination?

Immune checkpoint inhibitors thumb

Room: Hall B3 – Room 22, 13:00-14:30
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details

Learning Objectives
  • To look at different ways of combining immune checkpoints inhibitors with same or different classes of treatment
  • To consider the potential adverse events
  • To review the present data in lung and breast cancer
  • To understand the role of potential predictive factors
  • To put in perspective the magnitude of clinical benefit compared to other alternatives

Sunday, 21 October 2018

ESMO Colloquium: Acute myeloid leukaemia: Focus on FLT3-ITD mutation

Acute myeloid leukaemia thumb

Room: Hall A1 – Room 15, 18:30-20:00
This educational activity is provided by ESMO and supported by Daiichi Sankyo.
View the ESMO colloquium details

Learning Objectives
  • To dissect acute myeloid leukemias from a molecular alteration point of view
  • To put the present molecular characterization in perspective with guidelines
  • To address the specificities of FTL3-ITD mutated subtype
  • To review the present achievements with the use of molecular targeted approaches

Sunday, 21 October 2018

ESMO Colloquium: Are Biosimilars the key to access, in practice?

Are Biosimilars the key to access thumb

Room: Hall A1– Room 16, 18:30-20:00
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO colloquium details

Learning Objectives
  • Build confidence around the use of biosimilars in oncology, by providing examples of existing biosimilar use in supportive care (eg. Growth factors & epoetins)
  • Understand the concerns patients may have while getting switched from an originator to a biosimilar
  • Inform the healthcare community about the existing challenges for the uptake of oncology biosimilars following the recent survey conducted by ESMO about modulating the efficacy of immunotherapy
  • Assess the financial impact of oncology biosimilars on healthcare systems

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings